利培酮与碳酸锂治疗躁狂发作对照研究
躁狂发作；利培酮；碳酸锂,,躁狂发作；利培酮；碳酸锂,【摘要】,【关键词】,1对象与方法,2结果,3讨论,参考文献
【摘要】 目的 比较利培酮与碳酸锂治疗躁狂发作的疗效及安全性。 方法 将80例躁狂发作患者随机分为利培酮组和碳酸锂组各40例，观察治疗4w，采用BechRafaelsen躁狂量表及副作用量表评定疗效和不良反应并进行对比分析。 结果 利培酮组治疗1w末RechRafaelsen躁狂量表总分比治疗前明显降低(P<0.05)，且显著低于碳酸锂组(P<0.05)；治疗4w末两组均显著低于治疗前(P<0.01)，组间比较无显著性差异(P>0.05)。副作用量表同期评定提示，利培酮组不良反应发生率较低，且程度较轻，患者耐受性好。 结论 利培酮治疗躁狂发作起效快，疗效肯定，不良反应较轻，治疗依从性好。【关键词】 躁狂发作；利培酮；碳酸锂
A control study of risperidone vs. lithium carbonate in the treatment of manic episode
Song Li, Zhu Yuxing , Zhang Guiping, et al
(Zhumadian Mental Hospital, Zhumadian 463000 ,Henan,China)
【Abstract】 Objective To compare the efficacy and safety of risperidone vs. lithium carbonate in the treatment of manic episode. Methods 80 patients with manic episode were randomly divided into research (n=40, risperidone) and control group (n=40,lithium carbonate) for 4 weeks. Efficacy were assessed with the BechRafaelsen Mania Rating Scale(BRMS) and side effects with the Treatment Emergent Symptom Scale(TESS) before and after treatment, respectively. Results At the end of the 1st week, the total score of BRMS in research group were obviously lower than that at pretreatment(P<0.05) and significantly lower than that in control group(P<0.05); at the end of 4th week, the total scores of BRMS in both 2 groups were significantly lower compared with pretreatment (P<0.01) and there was no significant difference between the 2 groups(P>0.05).The TESS showed that risperidone had fewer and milder side effects and welltolerance. Conclusion Risperidone takes effect quicker and has better efficacy, milder side effects and welltolerance in the treatment of manic episode. ......
您现在查看是摘要页，全文长 7025 字符。